Related Experiment Videos

Interleukin-12: a pivotal regulator of cell-mediated immunity

M K Gately¹, M J Brunda

¹Department of Inflammation/Autoimmune Diseases, Hoffmann-La Roche Inc., Nutley, New Jersey 07110-1199, USA.

Cancer Treatment and Research

|January 1, 1995

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis.

Journal of immunology (Baltimore, Md. : 1950)·2001

Peginterferon alfa-2a in patients with chronic hepatitis C.

The New England journal of medicine·2000

In vitro and in vivo responses to interleukin 12 are maintained until the late SIV infection stage but lost during AIDS.

AIDS research and human retroviruses·2000

Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice.

Clinical pharmacology and therapeutics·1999

IL-12 is dispensable for innate and adaptive immunity against low doses of Listeria monocytogenes.

International immunology·1999

Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas.

Journal of immunology (Baltimore, Md. : 1950)·1998

See all related articles